Clinical trials: Allergen Immunotherapy
- Condition Allergen Immunotherapy
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Allergic Rhinitis Due to House Dust Mite
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents
The purpose of this study is to investigate the safety and tolerability of different doses of sublingual tablets of house dust mite (HDM) allergen extracts in adolescents with house dust mite-associated allergic rhinitis.
- Trial name
- NCT01919554
- Testing
- 500 IR house dust mites allergen extract tablet, 1000 IR house dust mites allergen extract tablet, 1500 IR house dust mites allergen extract tablet
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Stallergenes Greer
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.
- Trial name
- NCT01700192
- Testing
- MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets
- Volunteers
- 1,482 people
- Sponsor
- ALK-Abelló A/S
Food Allergy
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
- Trial name
- NCT04856865
- Testing
- Low dose ADP101, High dose ADP101
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Allergy
Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis
A phase III study to evaluate the efficacy and safety of SLIT for grass pollen allergens compared with placebo for reduction of symptoms and rescue medication usage in children.
- Trial name
- NCT00409409
- Testing
- 300 IR grass pollen allergen extract tablet
- Where
- Germany
- Volunteers
- 278 people
- Sponsor
- Stallergenes Greer
Birch Pollen Allergy
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
Study aiming to evaluate the efficacy of a 2-month pre-seasonal treatment with an AllerT 50 µg or 100 µg maintenance dose administered in previous study AN004T in reducing symptoms of allergic rhinoconjunctivitis during the 2nd…
- Trial name
- NCT02143583
- Where
- 22 sites in Denmark, France and 5 more
- Volunteers
- 196 people
- Sponsor
- Anergis
Hen Egg Allergy
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
To determine the efficacy and safety of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
- Trial name
- NCT04056299
- Testing
- AR201 powder
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aimmune Therapeutics, Inc.
Allergic Rhinitis Due to Grass Pollens
Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.
- Trial name
- NCT00955825
- Testing
- 300 IR
- Where
- 19 sites in United States
- Volunteers
- 473 people
- Sponsor
- Stallergenes Greer
Peanut Allergy
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT™) regimen in peanut-allergic children.
- Trial name
- RAMSES (NCT03126227)
- Testing
- AR101
- Where
- 67 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
ARTEMIS Peanut Allergy In Children
The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.
- Trial name
- ARTEMIS (NCT03201003)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 18 sites in France, Germany and 5 more
- Volunteers
- 175 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
- Trial name
- NCT03292484
- Testing
- AR101
- Where
- 93 sites in United States, Canada and 8 more
- Volunteers
- 911 people
- Sponsor
- Aimmune Therapeutics, Inc.
Allergic Rhinitis Due to Dust Mite
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children
The purpose of this study is to assess the efficacy of one dose of sublingual immunotherapy (SLIT) administered to children and adolescents as allergen-based tablets once daily over a period of 24 months over 3 years compared to…
- Trial name
- NCT01199133
- Testing
- 300 IR house dust mites allergen extract tablet
- Volunteers
- 471 people
- Sponsor
- Stallergenes Greer
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to < 4 years.
- Trial name
- POSEIDON (NCT03736447)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 146 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
- Trial name
- PALISADE (NCT02635776)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 69 sites in United States, Canada and 8 more
- Volunteers
- 555 people
- Sponsor
- Aimmune Therapeutics, Inc.
Seasonal Allergic Rhinitis
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
The objective of this study is to assess the effect of grass pollen extract SLIT tablets on the Rhinoconjunctivitis Total Symptom Score (RTSS) of the six rhinoconjunctivitis symptoms in response to grass pollen challenge after…
- Trial name
- NCT00619827
- Testing
- 300 IR grass pollen allergen extract tablet
- Where
- Austria
- Volunteers
- 89 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic…
- Trial name
- NCT03558997
- Testing
- Dupilumab, Timothy Grass SCIT
- Where
- 17 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Regeneron Pharmaceuticals
Rhinoconjunctivitis, Rhinitis
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00550550
- Testing
- SCH 697243, Loratadine Syrup 1 mg/mL Rescue Treatment, Loratadine 10 mg Rescue Treatment
- Volunteers
- 345 people
- Sponsor
- ALK-Abelló A/S
Peanut Allergy
AR101 Real-World Open-Label Extension Study
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
- Trial name
- NCT03337542
- Testing
- AR101
- Where
- 60 sites in United States, Canada
- Volunteers
- 243 people
- Sponsor
- Aimmune Therapeutics, Inc.
Allergy
Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets
A phase III study to evaluate Long term efficacy , carry-over effect and safety of 300 IR sublingual Immunotherapy (SLIT) tablets in adults patients suffering from grass pollen rhinoconjunctivitis
- Trial name
- NCT00418379
- Testing
- 300 IR (4M), 300 IR (2M)
- Where
- France
- Volunteers
- 633 people
- Sponsor
- Stallergenes Greer
Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
The purpose of this study is to determine the proportion of participants that initiate allergen immunotherapy (AIT) upon the recommendation of their physician and the proportion of participants that persist with their AIT…
- Trial name
- NCT01549340
- Volunteers
- 8,790 people
- Sponsor
- ALK-Abelló A/S